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It is well established that cancer is a progressive disease,
occurring in a series of well-defined steps, typically arising
as a consequence of activating mutations (oncogenes) or
deactivating mutations (tumor suppressor genes) in prolif-
erating cells. From studies exploiting cultured tumor cells,
two-stage carcinogenesis protocols in mice, and transgenic
models of tumorigenesis, it is now evident that a single
mutagenic event does not result in formation of a malig-
nant tumor (1). Additional genetic and epigenetic events
are necessary for progression to the tumor state. Initiated
cells therefore require alterations rendering them self-suffi-
cient for growth, insensitive to growth-inhibitory signals,
resistant to programs of terminal differentiation, senes-
cence, or apoptosis, as well as endowing them with unlim-
ited self-renewal capacity, the ability to orchestrate and di-
rect sustained angiogenesis, and the ability to invade and
thrive in ectopic tissue environments (1). In this issue, Lin
et al. (2) report that CSF-1 expression is a critical factor in a
transgenic mouse model of mammary cancer development.
 
This study provides compelling data that one subset of
inflammatory cells, macrophages, and the dynamic micro-
 
environment in which they live facilitate malignant
outgrowth and eventual metastatic spread of evolving neo-
plastic cells.
CSF-1, a dimeric polypeptide growth factor, acts
through a cell surface tyrosine kinase receptor encoded by
 
the 
 
cfms
 
 protooncogene (3). This growth factor–receptor
complex is an important regulator of proliferation, differen-
tiation, and survival of macrophages and their bone mar-
row progenitors (3). Interestingly, elevated expression of
CSF-1 and 
 
cfms
 
 has long been associated with poor progno-
sis in several types of human epithelial cancer, e.g., breast,
uterine, and ovarian (4). Elevated expression of CSF-1 also
correlates with intense leukocyte infiltration during devel-
opment and progression of human breast and ovarian can-
cer (5, 6); however, the functional significance of increased
CSF-1 and infiltrating leukocytes in neoplastic tissue has
remained unclear. The study by Lin et al. provides a con-
nection between autocrine CSF-1 expression, macrophage
infiltration, and development of late-stage mammary carci-
noma and its pulmonary metastases (2). The broader impli-
cations of this study are that inflammatory cells potentiate
neoplastic progression via paracrine factors that are as im-
portant to tumor evolution as oncogenes and tumor sup-
pressor genes (Fig. 1).
In this study, the authors have crossed transgenic mice
susceptible to development of mammary cancer (PyMT
mice) with mice containing a recessive null mutation in the
 
CSF-1 gene (
 
Csf1
 
op
 
). Whereas absence of CSF-1 during
early neoplastic development is without apparent conse-
quence, development of late-stage invasive carcinoma and
its metastatic pulmonary derivatives are significantly attenu-
ated. The key difference between PyMT mice and PyMT/
 
Csf1
 
op
 
/Csf1
 
op
 
 
 
mice is not in the proliferative capacity of
neoplastic epithelial cells, but failure to recruit mature mac-
rophages into neoplastic tissue in the absence of CSF-1.
 
Macrophage recruitment is restored by restoring CSF-1
expression specifically to mammary epithelium in CSF-1–
null/PyMT mice, as was characteristic primary and meta-
static tumor development. A similar study shows that sub-
cutaneous growth of Lewis lung cancer is impaired in
 
Csf1
 
op
 
/Csf1
 
op
 
 
 
mice (7). However, in the latter example, tu-
mors display a decreased mitotic index and pronounced ne-
crosis, apparently resulting from diminished angiogenesis
and impaired tumor stroma formation. These defects can
be corrected by treatment of tumor-bearing mice with re-
combinant CSF-1 (7). Together, these genetic experiments
provide a causal link between CSF-1–dependent infiltrat-
ing macrophages and the malignant potential of epithelial
cells.
Although the association of various inflammatory cell
types with cancer is not new, with Westphal reporting
dense areas of mast cells at the periphery of tumor as early
as 1891 (8), until recently, inflammatory cells have been
largely ignored as “promoting” forces in tumor develop-
ment (Fig. 2). Several independent studies using human
clinical samples show that epithelial cell turnover is affected
by inflammation (9, 10). More significantly, proliferation in
the setting of chronic inflammation predisposes humans to
carcinoma in the breast, liver, large bowel, urinary bladder,
prostate, gastric mucosa, ovary, and skin (5, 9–13). Perhaps
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the best evidence for the importance of inflammation dur-
ing neoplastic progression comes from study of cancer risk
among long-term users of aspirin and nonsteroidal antiin-
flammatory drugs (NSAIDs). A large body of data indicates
that use of these drugs reduces colon cancer risk by 40–
50%, and may be preventative for lung, esophagus, and
stomach cancer (14, 15). The mechanism(s) underlying the
chemopreventive effects of NSAIDs has to do with their
ability to inhibit cyclooxygenases (COX-1 and COX-2).
COX-2 converts arachidonic acid to prostaglandins, which
in turn induces inflammatory reactions in damaged tissues
(16).
What do infiltrating inflammatory cells provide to evolv-
ing neoplasms? The inflammatory component of a devel-
oping neoplasm includes a diverse leukocyte population,
e.g., macrophages, neutrophils, eosinophils, and mast cells,
all of which are variably loaded with an assorted array of
cytokines, cytotoxic mediators including reactive oxygen
species, serine-, cysteine-, and metallo-proteases, mem-
brane-perforating agents, and soluble mediators of cell kill-
ing, such as TNF-
 
a
 
, ILs, and IFNs (9, 17, 18). Neutrophils
(PMNs) are the most abundant circulating blood leuko-
cytes. They provide the first line of defense against infec-
tion and release soluble chemotactic factors and proteases
that alter the microenvironment and guide the recruitment
of both nonspecific and specific immune effector cells (17).
Mast cells play an important role in acute inflammation due
to their release of stored and newly synthesized inflamma-
tory mediators after activation. Mast cells release diverse
factors known to enhance angiogenic phenotypes, includ-
ing heparin, heparanase, histamine, metallo- and serine
proteinases, and various polypeptide growth factors, in-
cluding basic fibroblast growth factor (bFGF) and vascular
endothelial growth factor (VEGF; reference 19). Thus,
mast cells provide direct mitogens for fibroblasts, endothe-
lial, and epithelial cells, as well as diverse enzymatic activi-
ties involved in (extracellular matrix [ECM]) remodeling.
Eosinophils, which have many bioactive molecules in their
granules, are generally regarded as cells recruited to tissue as
a host defense against parasites or during allergic responses
(20). Macrophages produce several potent angiogenic cy-
tokines, growth factors, and proteases. Macrophage infiltra-
tion is closely associated with the depth of invasion of pri-
mary melanoma due, in part, to macrophage-regulated
tumor-associated angiogenesis (21). Macrophages express
many bioactive molecules, including proteases, arachido-
Figure 1. Tumors consist of neoplastic epithelial
cells and their microenvironment. ECM in and
around the forming tumor is populated with capil-
laries and their support cells (pericytes, smooth
muscle cells, and fibroblasts), and inflammatory cells
(macrophages, PMNs, and mast cells).
Figure 2. Epithelial-stromal cross-talk during neoplastic
progression. Epithelial neoplasia is initiated with muta-
tional events; however, these cells remain dormant until
wounding or tumor promoters activate the quiescent stro-
mal cells. These promotion events recruit and activate in-
flammatory cells such as PMNs, macrophages (Mf), or
mast cells (MCs). In turn, these activated inflammatory
cells stimulate growth and progression of the epithelial cells
to form a benign tumor. These cells further activate addi-
tional inflammation and the ensuing angiogenesis, ECM
remodeling. This altered microenvironment further desta-
bilizes the epithelial cells to undergo malignant conversion
to full carcinomas and facilitate metastasis. 
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nate metabolites, TGF-
 
b
 
, TNF-
 
a
 
, and IL-1
 
a
 
 (20). In re-
sponse, melanocytes express IL-8 and VEGF, thereby in-
ducing angiogenesis through paracrine control (22).
But macrophages are not unique among inflammatory
cells in potentiation of neoplastic processes. PMNs, mast
cells, and activated T lymphocytes can also contribute to
malignancies by releasing proteases, angiogenic factors, and
chemokines (9, 17, 19, 23, 24). Mast cells and neutrophils
also potentiate the actions of oncogenes encoded by human
papillomavirus type 16 (HPV16) in transgenic mice predis-
posed to squamous carcinoma development (19, 23). These
data support a model in which mast cells, macrophages, and
PMNs amplify neoplastic cell proliferation and angiogene-
sis largely by release of matrix metalloproteinase-9 (MMP-
9). HPV16 mice carrying a homozygous null mutation in
the MMP-9 gene have decreased epithelial proliferation,
delayed angiogenesis, reduced tumor incidence, and altered
differentiation characteristics of rarer emergent tumors (23).
As infiltration of neoplastic tissues by mast cells and PMNs
is not impaired in HPV16/MMP-9–deficient mice (un-
published observations), the data suggest that MMP-9 is a
key factor released by these leukocytes mediating potentia-
tion of tumorigenic progression.
How do inflammatory cells get co-opted into the neo-
plastic process? A plausible hypothesis is that many malig-
nancies arise from areas of infection and inflammation, sim-
ply as part of the normal host response. Indeed, there is a
growing body of evidence that many malignancies, e.g.,
gastric, cervical, and colon, are initiated by infections (9,
25). In fact, upwards of 15% of malignancies worldwide
can be attributed to infections, a global total of 1.2 million
cases per year (9). The three main mechanisms by which
infections can cause cancer involve initiation as well as pro-
motion (for a review, see reference 9). Persistent infections
within the host induce chronic inflammation. Leukocytes
and other phagocytic cells induce DNA damage in prolifer-
ating cells through their generation of reactive oxygen and
nitrogen species that are produced normally by these cells
in order to fight infection (26). Unfortunately, these react
to form peroxynitrite, a mutagenic agent (26). Hence, re-
peated tissue damage and regeneration of tissue in the pres-
ence of highly reactive nitrogen and oxygen species, re-
leased from inflammatory cells, interacts with DNA in
proliferating epithelium resulting in permanent genomic al-
terations, e.g., point mutations, deletions, or rearrange-
ments. The gram-negative bacterium 
 
Helicobacter pylori 
 
is
established as a definite carcinogen for the development of
gastric cancer, the second most common type of cancer
globally (9, 25). Infection by 
 
H. pylori
 
 has a very high can-
cer-associated risk of 75% (25). DNA damage resulting
from chronic inflammation is believed to be the mecha-
nism. Exacerbating DNA damage induced by inflammatory
cells is expression of macrophage migration inhibitory fac-
tor (MIF) by macrophages and T lymphocytes. MIF is a
potent cytokine that overcomes p53 function by suppress-
ing its transcriptional activity (27). Chronic bypass of p53
regulatory functions in infiltrated tissues can enhance pro-
liferation and extend life span, while also creating an envi-
 
ronment with a deficient response to DNA damage, ampli-
fying accumulation of potential oncogenic mutations.
Infectious agents may also directly transform cells by in-
serting active oncogenes into the host genome, e.g., DNA
tumor viruses and human immunodeficiency. It is clear
that many types of infectious agents, particularly viruses, are
present in mammals. However, virus-associated malignan-
cies are relatively rare in infected individuals. This likely re-
flects the necessity of cofactors necessary for promotion and
the fact that a neoplasia can only develop if viral infection
has affected that tissues pluripotent stem cells, as differenti-
ated cells are not easily immortalized. Although this does
occur, stem cells are typically low in abundance and located
in regions of tissues protected from agents that would oth-
erwise harm them (28). In Rous sarcoma virus infections,
inflammation is essential for tumor development, and this
requirement is mediated by factors such as TGF-
 
b
 
 and
other cytokines produced by the inflammatory cells (29).
Another intriguing possibility arises from the observation
that leukocyte adhesion molecules are required for effective
tumor progression (30). Just as microorganisms hijack mac-
rophages for growth and spread, perhaps the formation of
tumor-platelet-leukocyte emboli allows tumor cells to pig-
gyback on macrophages and other leukocytes to their in-
teractions with the endothelium of distant organs.
Are tumor-associated macrophages and other inflamma-
tory cells targets for cancer therapy? The incredible efficacy
of NSAIDs in chemoprevention argues for antiinflammatory
therapy at the earliest stages of neoplastic progression. Al-
though the results with CSF-1 suggest that macrophages
contribute to metastasis (2), inflammatory and other im-
mune cells undoubtedly also take part in antitumor surveil-
lance. In the absence of certain cells or functions, it is possi-
ble that some tumors will progress more rapidly (19, 20, 24).
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